Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · Real-Time Price · USD
3.140
-0.280 (-8.19%)
At close: Feb 21, 2025, 4:00 PM
3.200
+0.060 (1.91%)
After-hours: Feb 21, 2025, 6:14 PM EST
Lipella Pharmaceuticals Employees
As of December 31, 2023, Lipella Pharmaceuticals had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$69,076
Profits / Employee
-$609,068
Market Cap
3.80M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 0 | - |
Dec 31, 2022 | 7 | 2 | 40.00% |
Dec 31, 2021 | 5 | 0 | - |
Dec 31, 2020 | 5 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
LIPO News
- 11 days ago - Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - Benzinga
- 16 days ago - Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus - GlobeNewsWire
- 6 weeks ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - GlobeNewsWire
- 7 weeks ago - Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions - GlobeNewsWire
- 2 months ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - GlobeNewsWire
- 4 months ago - Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 5 months ago - PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - GlobeNewsWire
- 1 year ago - FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease - PRNewsWire